What are the treatment options for IDH2 mutant cancers?
Treatment options for IDH2 mutant cancers include traditional therapies such as chemotherapy, radiation, and surgery. Additionally, targeted therapies have been developed to specifically inhibit the mutant IDH2 enzyme. One such drug is Enasidenib (AG-221), which targets mutant IDH2 and has shown efficacy in treating IDH2-mutant AML. Ongoing clinical trials are exploring other potential inhibitors and combination therapies.
